These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14714044)

  • 21. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Free radicals, antioxidant defense systems, and schizophrenia.
    Wu JQ; Kosten TR; Zhang XY
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():200-6. PubMed ID: 23470289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
    Levin ED; Rezvani AH
    Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.
    Pillai A
    Neurosignals; 2008; 16(2-3):183-93. PubMed ID: 18253057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L
    J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Possible relevance of alterations at the cellular, neuronal connectivity and brain structure levels to the pathophysiology of schizophrenia].
    Berger E; Shiloh R; Weizman A; Munitz H
    Harefuah; 2001 Jul; 140(7):648-52. PubMed ID: 11481973
    [No Abstract]   [Full Text] [Related]  

  • 31. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.
    Boczek T; Mackiewicz J; Sobolczyk M; Wawrzyniak J; Lisek M; Ferenc B; Guo F; Zylinska L
    Cells; 2021 May; 10(5):. PubMed ID: 34067760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium signaling dysfunction in schizophrenia: a unifying approach.
    Lidow MS
    Brain Res Brain Res Rev; 2003 Sep; 43(1):70-84. PubMed ID: 14499463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia.
    Mahadik SP; Pillai A; Joshi S; Foster A
    Int Rev Psychiatry; 2006 Apr; 18(2):119-31. PubMed ID: 16777666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Redox and microglia in the pathophysiology of schizophrenia].
    Kato TA; Hyodo F; Yamato M; Utsumi H; Kanba S
    Yakugaku Zasshi; 2015; 135(5):739-43. PubMed ID: 25948311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammation in schizophrenia: A question of balance.
    Leza JC; García-Bueno B; Bioque M; Arango C; Parellada M; Do K; O'Donnell P; Bernardo M
    Neurosci Biobehav Rev; 2015 Aug; 55():612-26. PubMed ID: 26092265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic mechanisms in the pathogenesis of schizophrenia.
    Goldstein M; Deutch AY
    FASEB J; 1992 Apr; 6(7):2413-21. PubMed ID: 1348713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic drug action: targets for drug discovery with neurochemical imaging.
    Stone JM; Pilowsky LS
    Expert Rev Neurother; 2006 Jan; 6(1):57-64. PubMed ID: 16466312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis.
    Rogers DP; Goldsmith CA
    Expert Rev Neurother; 2009 Jan; 9(1):47-54. PubMed ID: 19102668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.